These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34724850)

  • 1. Dopamine receptor agonist rotigotine-loaded microspheres ameliorates sexual function deteriorated by fluoxetine in depression rats.
    Wang W; Zhang C; Fan Y; Yue S; Yang Y; Liu R; Zhang L; Wang T; Fu F
    ASN Neuro; 2021; 13():17590914211052862. PubMed ID: 34724850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipopolysaccharide/D-galactosamine-induced acute liver injury could be attenuated by dopamine receptor agonist rotigotine via regulating NF-κB signaling pathway.
    Yue S; Wang T; Yang Y; Fan Y; Zhou L; Li M; Fu F
    Int Immunopharmacol; 2021 Jul; 96():107798. PubMed ID: 34162160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antinociceptive effects of rotigotine-loaded microspheres and its synergistic interactions with analgesics in inflammatory pain in rats.
    Li T; Wang T; Wang L; Liu R; Zhang L; Zhai R; Fu F
    Eur J Pharmacol; 2021 Jan; 891():173693. PubMed ID: 33160937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rotigotine and rotigotine extended-release microsphere therapy on myocardial ischemic injury in mice.
    Lv H; Yu F; Sha C; Huang Y; Lu Y; Zhang L; Zhai R; Wang T; Fu F
    Eur J Pharm Sci; 2019 Jun; 134():1-6. PubMed ID: 30959104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotigotine-loaded microspheres exerts the antinociceptive effect via central dopaminergic system.
    Li T; Wang L; Zhang L; Li B; Wang D; Zhang L; Wang T; Fu F
    Eur J Pharmacol; 2021 Nov; 910():174443. PubMed ID: 34464604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.
    Wang A; Wang L; Sun K; Liu W; Sha C; Li Y
    Pharm Res; 2012 Sep; 29(9):2367-76. PubMed ID: 22549738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.
    Ye L; Guan X; Tian J; Zhang J; Du G; Yu X; Yu P; Cen X; Liu W; Li Y
    Food Chem Toxicol; 2013 Jun; 56():81-92. PubMed ID: 23454207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres.
    Yu X; Yao JY; He J; Tian JW
    Life Sci; 2015 Mar; 124():136-43. PubMed ID: 25640758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant properties of rotigotine in experimental models of depression.
    Bertaina-Anglade V; La Rochelle CD; Scheller DK
    Eur J Pharmacol; 2006 Oct; 548(1-3):106-14. PubMed ID: 16959244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
    Tian J; Du G; Ye L; Yu X; Zhang J; Wang H; Yu P; Fu F; Liu W; Li Y; Cen X; Guan X
    Food Chem Toxicol; 2013 Feb; 52():143-52. PubMed ID: 23165154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
    Fenu S; Espa E; Pisanu A; Di Chiara G
    Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
    Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
    Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The direct analysis of drug distribution of rotigotine-loaded microspheres from tissue sections by LESA coupled with tandem mass spectrometry.
    Xu LX; Wang TT; Geng YY; Wang WY; Li Y; Duan XK; Xu B; Liu CC; Liu WH
    Anal Bioanal Chem; 2017 Sep; 409(22):5217-5223. PubMed ID: 28702764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine: in Parkinson's disease.
    Reynolds NA; Wellington K; Easthope SE
    CNS Drugs; 2005; 19(11):973-81. PubMed ID: 16268667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
    Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
    Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes.
    Isooka N; Miyazaki I; Kikuoka R; Wada K; Nakayama E; Shin K; Yamamoto D; Kitamura Y; Asanuma M
    Neurochem Int; 2020 Jan; 132():104608. PubMed ID: 31765686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.